The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

about

Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment

P2860

Q27005680-0646CA06-89FC-46C5-89E1-5A9A10BA68F8

P2860

The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

Item

http://www.wikidata.org/entity/Q54349169

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@en

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@nl

type

Item

label

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@en

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@nl

prefLabel

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@en

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@nl

P1476

The tyrosine kinase inhibitor ...... orbital fibroblast activation.

@en

P2093

Dion Paridaens

http://www.w3.org/2001/XMLSchema#string

Nattiya Hirankarn

http://www.w3.org/2001/XMLSchema#string

P Martin van Hagen

http://www.w3.org/2001/XMLSchema#string

Sita Virakul

http://www.w3.org/2001/XMLSchema#string

Virgil A S H Dalm

http://www.w3.org/2001/XMLSchema#string

Willem A Dik

http://www.w3.org/2001/XMLSchema#string

Willem A van den Bosch

http://www.w3.org/2001/XMLSchema#string

P2860

Graves' ophthalmopathy

Role of platelet-derived growth factors in physiology and medicine

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.

Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy.

Activity-based kinase profiling of approved tyrosine kinase inhibitors.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.

P2888

s00417-014-2674-7

P304

1101-1109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00417-014-2674-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

252

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262779478

http://www.w3.org/2001/XMLSchema#string

P698

24874745

http://www.w3.org/2001/XMLSchema#string

The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

about

P2860

P2860

The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698